664 related articles for article (PubMed ID: 33750684)
21. Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer.
Aggarwal R; Wei X; Kim W; Small EJ; Ryan CJ; Carroll P; Cooperberg M; Evans MJ; Hope T
Eur Urol Oncol; 2018 May; 1(1):78-82. PubMed ID: 31100231
[TBL] [Abstract][Full Text] [Related]
22.
Fassbind S; Ferraro DA; Stelmes JJ; Fankhauser CD; Guckenberger M; Kaufmann PA; Eberli D; Burger IA; Kranzbühler B
Ann Nucl Med; 2021 Oct; 35(10):1109-1116. PubMed ID: 34185262
[TBL] [Abstract][Full Text] [Related]
23. Treatment outcomes of metastasis-directed treatment using
Hurmuz P; Onal C; Ozyigit G; Igdem S; Atalar B; Sayan H; Akgun Z; Kurt M; Ozkok HB; Selek U; Oymak E; Tilki B; Guler OC; Mustafayev TZ; Saricanbaz I; Rzazade R; Akyol F
Strahlenther Onkol; 2020 Nov; 196(11):1034-1043. PubMed ID: 32617620
[TBL] [Abstract][Full Text] [Related]
24. Toxicity and Efficacy of Local Ablative, Image-guided Radiotherapy in Gallium-68 Prostate-specific Membrane Antigen Targeted Positron Emission Tomography-staged, Castration-sensitive Oligometastatic Prostate Cancer: The OLI-P Phase 2 Clinical Trial.
Hölscher T; Baumann M; Kotzerke J; Zöphel K; Paulsen F; Müller AC; Zips D; Koi L; Thomas C; Löck S; Krause M; Wirth M; Lohaus F
Eur Urol Oncol; 2022 Feb; 5(1):44-51. PubMed ID: 34785189
[TBL] [Abstract][Full Text] [Related]
25. Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review.
Battaglia A; De Meerleer G; Tosco L; Moris L; Van den Broeck T; Devos G; Everaerts W; Joniau S
Eur Urol Oncol; 2019 Mar; 2(2):174-188. PubMed ID: 31017094
[TBL] [Abstract][Full Text] [Related]
26. The Role of Magnetic Resonance Imaging and Positron Emission Tomography/Computed Tomography in the Primary Staging of Newly Diagnosed Prostate Cancer: A Systematic Review of the Literature.
Abrams-Pompe RS; Fanti S; Schoots IG; Moore CM; Turkbey B; Vickers AJ; Walz J; Steuber T; Eastham JA
Eur Urol Oncol; 2021 Jun; 4(3):370-395. PubMed ID: 33272865
[TBL] [Abstract][Full Text] [Related]
27. Role of PSMA PET-guided metastases-directed therapy in oligometastatic recurrent prostate cancer.
Alberto M; Yim A; Papa N; Siva S; Ischia J; Touijer K; Eastham JA; Bolton D; Perera M
Front Oncol; 2022; 12():929444. PubMed ID: 36059632
[TBL] [Abstract][Full Text] [Related]
28. The Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Magnetic Resonance Imaging in Primary and Recurrent Prostate Cancer: A Systematic Review of the Literature.
Manfredi C; Fernández-Pascual E; Arcaniolo D; Emberton M; Sanchez-Salas R; Artigas Guix C; Bianco F; Cathcart P; Murphy DG; Couñago F; Martínez-Ballesteros C; Verze P; Martínez-Salamanca JI
Eur Urol Focus; 2022 Jul; 8(4):942-957. PubMed ID: 34538633
[TBL] [Abstract][Full Text] [Related]
29. PSMA-11-PET/CT versus choline-PET/CT to guide stereotactic ablative radiotherapy for androgen deprivation therapy deferral in patients with oligometastatic prostate cancer.
Deijen CL; Vrijenhoek GL; Schaake EE; Vogel WV; Moonen LMF; Pos FJ; van der Poel HG; Borst GR
Clin Transl Radiat Oncol; 2021 Sep; 30():1-6. PubMed ID: 34278008
[TBL] [Abstract][Full Text] [Related]
30. Benefits of Using Stereotactic Body Radiotherapy in Patients With Metachronous Oligometastases of Hormone-Sensitive Prostate Cancer Detected by [18F]fluoromethylcholine PET/CT.
Bouman-Wammes EW; van Dodewaard-De Jong JM; Dahele M; Cysouw MCF; Hoekstra OS; van Moorselaar RJA; Piet MAH; Verberne HJ; Bins AD; Verheul HMW; Slotman BJ; Oprea-Lager DE; Van den Eertwegh AJM
Clin Genitourin Cancer; 2017 Oct; 15(5):e773-e782. PubMed ID: 28462855
[TBL] [Abstract][Full Text] [Related]
31. Serial stereotactic body radiation therapy for oligometastatic prostate cancer detected by novel PET-based radiotracers.
Kwon DH; Shakhnazaryan N; Shui D; Hong JC; Mohamad O; de Kouchkovsky I; Borno HT; Bose R; Chou J; Desai A; Fong L; Friedlander TW; Koshkin VS; Aggarwal RR; Feng FY; Hope TA; Small EJ
Urol Oncol; 2023 Mar; 41(3):145.e7-145.e15. PubMed ID: 36435709
[TBL] [Abstract][Full Text] [Related]
32. Sensitivity, Specificity, and Predictors of Positive
Perera M; Papa N; Christidis D; Wetherell D; Hofman MS; Murphy DG; Bolton D; Lawrentschuk N
Eur Urol; 2016 Dec; 70(6):926-937. PubMed ID: 27363387
[TBL] [Abstract][Full Text] [Related]
33. Whole-body diffusion-weighted magnetic resonance imaging (WB-DW-MRI) vs choline-positron emission tomography-computed tomography (choline-PET/CT) for selecting treatments in recurrent prostate cancer.
Conde-Moreno AJ; Herrando-Parreño G; Muelas-Soria R; Ferrer-Rebolleda J; Broseta-Torres R; Cozar-Santiago MP; García-Piñón F; Ferrer-Albiach C
Clin Transl Oncol; 2017 May; 19(5):553-561. PubMed ID: 27796820
[TBL] [Abstract][Full Text] [Related]
34. Protocol for CHAMPION study: a prospective study of maximal-cytoreductive therapies for patients with de novo metastatic hormone-sensitive prostate cancer who achieve oligopersistent metastases during systemic treatment with apalutamide plus androgen deprivation therapy.
Wang B; Pan J; Zhang T; Ni X; Wei Y; Li X; Fang B; Hu X; Gan H; Wu J; Wang H; Ye D; Zhu Y
BMC Cancer; 2024 May; 24(1):643. PubMed ID: 38796422
[TBL] [Abstract][Full Text] [Related]
35. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
36.
Artigas C; Flamen P; Charlier F; Levillain H; Wimana Z; Diamand R; Albisinni S; Gil T; Velthoven RV; Peltier A; Gestel DV; Roumeguere T; Otte FX
World J Urol; 2019 Aug; 37(8):1535-1542. PubMed ID: 30824985
[TBL] [Abstract][Full Text] [Related]
37. Comparison of Hormone-Sensitive Oligorecurrent Prostate Cancer Patients Based on Routine Use of Choline and/or PSMA PET/CT to Guide Metastasis-Directed Therapy.
Metz R; Rauscher A; Vaugier L; Supiot S; Drouet F; Campion L; Rousseau C
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980784
[TBL] [Abstract][Full Text] [Related]
38. Rationale for Modernising Imaging in Advanced Prostate Cancer.
Padhani AR; Lecouvet FE; Tunariu N; Koh DM; De Keyzer F; Collins DJ; Sala E; Fanti S; Vargas HA; Petralia G; Schlemmer HP; Tombal B; de Bono J
Eur Urol Focus; 2017 Apr; 3(2-3):223-239. PubMed ID: 28753774
[TBL] [Abstract][Full Text] [Related]
39. Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature.
Ost P; Bossi A; Decaestecker K; De Meerleer G; Giannarini G; Karnes RJ; Roach M; Briganti A
Eur Urol; 2015 May; 67(5):852-63. PubMed ID: 25240974
[TBL] [Abstract][Full Text] [Related]
40. Clinical Translation of Positive Metastases Identified on Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging in the Management of De Novo Synchronous Oligometastatic Prostate Cancer.
Connor MJ; Dubash S; Bass EJ; Tam H; Barwick T; Khoo V; Winkler M; Ahmed HU
Eur Urol Focus; 2021 Sep; 7(5):951-954. PubMed ID: 33384271
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
